286 related articles for article (PubMed ID: 9835899)
21. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
22. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
23. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.
Karanes C; Kopecky KJ; Head DR; Grever MR; Hynes HE; Kraut EH; Vial RH; Lichtin A; Nand S; Samlowski WE; Appelbaum FR
Leuk Res; 1999 Sep; 23(9):787-94. PubMed ID: 10475617
[TBL] [Abstract][Full Text] [Related]
24. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
Larson RA; Day RS; Azarnia N; Bennett JM; Browman G; Goldberg J; Gottlieb A; Grunwald H; Miller K; Raza A
Br J Haematol; 1992 Oct; 82(2):337-46. PubMed ID: 1419816
[TBL] [Abstract][Full Text] [Related]
25. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Robak T; Wrzesień-Kuś A; Lech-Marańda E; Kowal M; Dmoszyńska A
Leuk Lymphoma; 2000 Sep; 39(1-2):121-9. PubMed ID: 10975390
[TBL] [Abstract][Full Text] [Related]
26. Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Hurwitz CA; Krance R; Schell MJ; Santana VM; Brenner MK; Ribeirio R; Roberts WM; Mahmoud H; Belt J; Crom W
Leukemia; 1992; 6 Suppl 2():39-43. PubMed ID: 1374492
[TBL] [Abstract][Full Text] [Related]
27. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
Brito-Babapulle F; Catovsky D; Slocombe G; Newland AC; Marcus RE; Goldman JM; Galton DA
Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
Daenen S; Löwenberg B; Sonneveld P; van Putten WL; Verhoef G; Verdonck LF; van Veldhoven M; Huijgens PC
Leukemia; 1994 Jan; 8(1):6-10. PubMed ID: 8289499
[TBL] [Abstract][Full Text] [Related]
30. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation.
Sierra J; Brunet S; Grañena A; Olivé T; Bueno J; Ribera JM; Petit J; Besses C; Llorente A; Guardia R; Macía J; Rovira M; Badell I; Vela E; Díaz de Heredia C; Vivancos P; Carreras E; Feliu E; Montserrat E; Julía A; Cubells J; Rozman C; Domingo A; Ortega JJ
J Clin Oncol; 1996 Apr; 14(4):1353-63. PubMed ID: 8648394
[TBL] [Abstract][Full Text] [Related]
31. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
Clavio M; Carrara P; Miglino M; Pierri I; Canepa L; Balleari E; Gatti AM; Cerri R; Celesti L; Vallebella E; Sessarego M; Patrone F; Ghio R; Damasio E; Gobbi M
Haematologica; 1996; 81(6):513-20. PubMed ID: 9009438
[TBL] [Abstract][Full Text] [Related]
32. A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML).
Leahey A; Kelly K; Rorke LB; Lange B
J Pediatr Hematol Oncol; 1997; 19(4):304-8. PubMed ID: 9256828
[TBL] [Abstract][Full Text] [Related]
33. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology.
Gentet JC; Patte C; Quintana E; Bergeron C; Rubie H; Pein F; Demaille MC; Philip T; Raybaud C
J Clin Oncol; 1990 Apr; 8(4):661-5. PubMed ID: 2313335
[TBL] [Abstract][Full Text] [Related]
35. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
Advani R; Visani G; Milligan D; Saba H; Tallman M; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Covelli A; Sikic B; Greenberg P
Adv Exp Med Biol; 1999; 457():47-56. PubMed ID: 10500779
[TBL] [Abstract][Full Text] [Related]
36. A pilot study of continuous infusion Ara-C in combination with rhG-CSF in relapsed childhood acute myeloid leukemia.
Laver J; Shearer P; Krance R; Hurwitz CA; Srivastava DK; Weinstein HJ; Mirro J
Leuk Lymphoma; 1997 Aug; 26(5-6):589-93. PubMed ID: 9389365
[TBL] [Abstract][Full Text] [Related]
37. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
[TBL] [Abstract][Full Text] [Related]
38. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience.
Vignetti M; Orsini E; Petti MC; Moleti ML; Andrizzi C; Pinto RM; Amadori S; Meloni G
Ann Oncol; 1996 Nov; 7(9):933-8. PubMed ID: 9006744
[TBL] [Abstract][Full Text] [Related]
39. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
Thomas X; Fenaux P; Dombret H; Delair S; Dreyfus F; Tilly H; Vekhoff A; Cony-Makhoul P; Leblond V; Troussard X; Cordonnier C; de Revel T; Simon M; Nicolini F; Stoppa AM; Janvier M; Bordessoule D; Rousselot P; Ffrench M; Marie JP; Archimbaud E
Leukemia; 1999 Aug; 13(8):1214-20. PubMed ID: 10450749
[TBL] [Abstract][Full Text] [Related]
40. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
